NLS Global report

It’s no small irony that one of the world’s most effective cancer drugs also is one of the least accessible.

French pharma company Servier has entered into an agreement to acquire the muscular dystrophy business of US Edgewise Therapeutics for up to USD 2.65 billion, including upfront payment of USD 1.55 billion as well as up to USD1.1 billion in regulatory and commercial milestone payments.

The Series B funding will be used to power the company's AI drug design engine, scale its business globally and progress its drug candidate pipeline.

The companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology.

BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts, it states. The company plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac’s sites, affecting up […]

Under the terms of the Transaction, Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for USD 27.00 per share in cash. The total value implied by the transaction at closing is approximately USD 1.9 billion.